Open AccessPatient after myocardial infarction: how to reduce the risk of recurrent ischemic events?
Author(s) -
О. Л. Барбараш,
Барбараш Ольга Леонидовна,
В. Н. Каретникова,
Каретникова Виктория Николаевна,
В. В. Кашталап,
Кашталап Василий Васильевич
Publication year - 2015
Publication title -
cardiosomatika
Language(s) - English
Resource type - Journals
eISSN - 2658-5707
pISSN - 2221-7185
DOI - 10.26442/cs45109
Subject(s) - medicine , myocardial infarction , ticagrelor , timi , cardiology , acute coronary syndrome , regimen , clinical trial , intensive care medicine , conventional pci
The review article highlights concerns related to a low survival rate in patients after myocardial infarction (MI) and factors affecting it. The pivotal role is given to the issue of patient adherence to therapy after acute coronary events. The options to improve it as well as mechanisms to optimize medical therapy for patients after myocardial infarction, particularly the need for prolonged dual antiplatelet therapy (DAPT), have been identified. The rationale for changing the current guidelines for the management of patients with acute coronary syndromes (ACS) is based on the findings of the recently completed international clinical trial PE- GASUS-TIMI 54 with ticagrelor (Brilinta®), utilized as part of a DAPT regimen, that have demonstrated the efficacy and safety of DAPT prolongation after 12-month period in post-MI patients.